Virax Biolabs Group (NASDAQ:VRAX – Get Rating) and Alpha Teknova (NASDAQ:TKNO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings & Valuation

This table compares Virax Biolabs Group and Alpha Teknova's gross revenue, earnings per share and valuation.

Get Virax Biolabs Group alerts:

Virax Biolabs Group has higher earnings, but lower revenue than Alpha Teknova.

Insider and Institutional Ownership

24.6% of Alpha Teknova shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Virax Biolabs Group and Alpha Teknova, as reported by MarketBeat.com.

Alpha Teknova has a consensus price target of $22.50, suggesting a potential upside of 469.62%. Given Alpha Teknova's higher probable upside, analysts clearly believe Alpha Teknova is more favorable than Virax Biolabs Group.

Profitability

This table compares Virax Biolabs Group and Alpha Teknova's net margins, return on equity and return on assets.

Summary

Alpha Teknova beats Virax Biolabs Group on 5 of the 8 factors compared between the two stocks.

About Virax Biolabs Group

(Get Rating)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.

About Alpha Teknova

(Get Rating)

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.